According to the recent Institute of Medicine (IOM) report on Relieving Pain in America (2011), chronic pain is a public health epidemic affecting more than 116 million Americans and costing more than $600 billion per year in healthcare expenses and lost work productivity. More Americans suffer from pain than those afflicted with heart disease, diabetes and cancer combined. Despite recent advances in treatment, most patients do not obtain adequate pain relief. The purpose of this Center in the Genomics of Pain is to promote pain research that incorporates rigorous phenotyping of pain and comorbid conditions with cutting edge genomics to more fully understand how individual differences can reduce or amplify pain. The Genomics Core (GC) is a critical component of the Center for the Genomics of Pain because it provides services and support for basic science and clinical investigators to combine and integrate phenotype and genotype/genomics analyses. To achieve the Center goals and those of the individual pilot studies, the GC will provide services in genomics assays (microarray, sequencing, genotyping), bioinformatics analysis and visualization of molecular genetics, genomics, genetic epidemiology, and clinical and translational genomics research data. For the first time on the UMB campus, these resources will be centralized and coordinated specifically for pain research. The GC will operate with the following four aims:
Aim 1. Molecular Genomics. The Core will provide DNA sequence analysis;mutation detection;low, medium, and high throughput single nucleotide polymorphism (SNP) genotyping;gene expression profiling via microarray;real time RT-PCR;RNA, DNA and exome sequencing;and other general molecular biology and genetics methods, such as DNA/RNA extraction with qualitative and quantitative analysis.
Aim 2. Data Management and Processing. The Core will provide efficient data management including edit checking of data to maintain data quality, facilitation of data transfer from one project to another, short and long-term storage and maintenance of data security. In addition, the Core will help to maintain and manage a Center database of genomic and phenotype data available for Center members to mine;these data will reside on the Center mainframe computer.
Aim 3. Genetic/Genomic Data Analysis and Bioinformatics. The Core will provide the expertise in genetic/genomic data analysis and bioinformatics tools for genomic discovery and gene expression studies. In addition, this Core will provide statistical tools to integrate phenotype and genomics data so that models of pain susceptibility can be developed and tested. The core will apply and develop various statistical, computational, bioinformatics and data visualization tools to meet the needs of each project for genomic analysis. Exploratory Aim/Future Direction?Clinical/Translational Genomics. The Core will facilitate clinical and translational research, including studies based on genotype-driven recruitment and other genomic-based approaches to understand functional consequences and underlying mechanisms of genetic variation and to develop novel clinical applications. For example, if Center investigators identify a SNP associated with pain susceptibility, we will work to integrate the """"""""clinically actionable"""""""" SNP into the electronic health record.
|Page, Gayle G; Corwin, Elizabeth J; Dorsey, Susan G et al. (2018) Biomarkers as Common Data Elements for Symptom and Self-Management Science. J Nurs Scholarsh 50:276-286|
|Griffith, Kathleen A; Zhu, Shijun; Johantgen, Meg et al. (2017) Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer. J Pain Symptom Manage 54:701-706.e1|
|Marmiroli, Paola; Riva, Beatrice; Pozzi, Eleonora et al. (2017) Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights. PLoS One 12:e0186250|
|Starkweather, Angela R; Heineman, Amy; Storey, Shannon et al. (2016) Methods to measure peripheral and central sensitization using quantitative sensory testing: A focus on individuals with low back pain. Appl Nurs Res 29:237-41|
|Moore, Shirley M; Schiffman, Rachel; Waldrop-Valverde, Drenna et al. (2016) Recommendations of Common Data Elements to Advance the Science of Self-Management of Chronic Conditions. J Nurs Scholarsh 48:437-47|
|Wu, Junfang; Zhao, Zaorui; Zhu, Xiya et al. (2016) Cell cycle inhibition limits development and maintenance of neuropathic pain following spinal cord injury. Pain 157:488-503|
|Resnick, Barbara; Klinedinst, N Jennifer; Yerges-Armstrong, Laura et al. (2016) Pain, Genes, and Function in the Post-Hip Fracture Period. Pain Manag Nurs 17:181-96|
|Starkweather, Angela R; Lyon, Debra E; Kinser, Patricia et al. (2016) Comparison of Low Back Pain Recovery and Persistence: A Descriptive Study of Characteristics at Pain Onset. Biol Res Nurs 18:401-10|
|Wu, Junfang; Zhao, Zaorui; Kumar, Alok et al. (2016) Endoplasmic Reticulum Stress and Disrupted Neurogenesis in the Brain Are Associated with Cognitive Impairment and Depressive-Like Behavior after Spinal Cord Injury. J Neurotrauma 33:1919-1935|
|Hertz, Daniel L; Owzar, Kouros; Lessans, Sherrie et al. (2016) Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res 22:4890-4900|
Showing the most recent 10 out of 18 publications